Roger joined Flagship Pioneering in 2014 and focuses on providing strategic counsel and support to the Flagship team as well as to portfolio companies through board and advisory roles. He is president, chief executive officer and chairman of Seres Therapeutics, a Flagship VentureLabs-founded company.
Roger was previously senior vice president and worldwide head of licensing & acquisitions at Merck & Co., Inc. where he oversaw all licensing and acquisitions at Merck Research Laboratories, including external research, out-licensing regional deals and academic alliances. Previously, he served as senior vice president and global franchise head of infectious diseases at Merck. Prior to joining Merck, Roger was global head of infectious diseases for Johnson & Johnson Pharmaceuticals, responsible for all anti-infective agents worldwide. He joined Johnson & Johnson in 2005 as president of Tibotec Pharmaceuticals, Inc.
Roger received his B.A. in biochemistry at the Johns Hopkins University and his M.D. at the Johns Hopkins School of Medicine. He completed his internal medicine internship and residency training, and his subspecialty clinical and research training in infectious diseases and virology at the Massachusetts General Hospital (MGH) and served as the chief medical resident at MGH. His post-doctoral research training in molecular retrovirology was obtained at both the Harvard Medical School and the Whitehead Institute of the Massachusetts Institute of Technology, in the laboratory of Nobel Laureate Dr. David Baltimore. Subsequently, Roger was professor of medicine, biochemistry and molecular pharmacology, chief of infectious diseases, and the founding director and chair of the Institute for Human Virology and Biodefense at the Thomas Jefferson University and Medical School in Philadelphia, PA.